HCM stock gains on GSK oncology deal and fresh guidance
Published on 09/05/2026 at 14:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
HUTCHMED (China) Limited stock (ISIN US44842L1035) is benefiting from a new licensing agreement with GSK and updated 2026 guidance, with the Hong Kong listing recently quoted at HKD 21.36 as of September 3, 2026 alongside a market capitalization of HKD 19,676.15 million according to an ad-hoc-news market snapshot.
Licensing deal with GSK boosts visibility
According to a law firm announcement dated September 4, 2026, HUTCHMED has signed a licensing agreement under which GSK receives worldwide rights, excluding mainland China, Hong Kong, Macau and Taiwan, to the experimental cancer therapy candidate HMPL-A830.
A separate industry summary reported that GSK will pay a HUTCHMED subsidiary USD 110 million upfront and that milestone payments linked to development, regulatory and commercial achievements could reach USD 1.185 billion, bringing the potential total value of the deal to USD 1.295 billion in oncology according to a pharmaceutical news compilation posted around September 4, 2026.
Fresh 2026 guidance and first-half 2026 figures
An ad-hoc-news summary of recent coverage noted that HUTCHMED now expects 2026 oncology and immunology revenue of USD 330 million to USD 450 million, giving investors a quantified range for the current fiscal year according to an article published on September 4, 2026.
The same report put HUTCHMED’s first-half 2026 total revenue at USD 278 million, with net income attributable to shareholders of USD 16.242 million and basic EPS of USD 0.02 for the period ended June 30, 2026, highlighting a profitable profile in the latest half-year.
More on HUTCHMED stock and fundamentals
For additional data on HCM stock, recent financial results and regulatory filings, visit the topic overview and the company’s investor information.
Analyst optimism and recent price performance
The recent ad-hoc-news coverage also noted that an investment bank raised its target price for HUTCHMED’s Hong Kong-listed shares to HKD 39 from HKD 36, while maintaining a positive view on the stock, signaling greater confidence in the company’s oncology portfolio and deal-driven revenue outlook.
On September 3, 2026, HUTCHMED’s Hong Kong shares were quoted at HKD 21.36, marking an 11.6 percent move on the day with trading volume of 11.6735 million shares and turnover of HKD 250 million, showing active investor interest according to the same ad-hoc-news data snapshot.
Key oncology product candidate HMPL-A830
HUTCHMED’s HMPL-A830 is described in the licensing announcement as a first-in-class KRAS-EGFR antibody-targeted therapy conjugate designed to selectively attack solid tumors, underlining the company’s focus on innovative targeted oncology treatments with global potential.
HCM stock and market context
HUTCHMED stock is listed on Nasdaq under the ticker HCM and on the Hong Kong Stock Exchange under stock code 13, with the Hong Kong shares quoted at HKD 21.36 as of September 3, 2026 in the latest available market snapshot.
HUTCHMED (China) Limited at a glance
- Company: HUTCHMED (China) Limited
- ISIN: US44842L1035
- Ticker: HCM
- Trading venue: HKEX and Nasdaq
- Price (as of September 3, 2026): 21.36 HKD
- Market capitalization: 19,676.15 million HKD (as of September 3, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Hong Kong healthcare universe
